Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

BACKGROUND: Chimeric antigen receptor T cells (CAR-Ts) constitute a novel therapeutic strategy for relapsed/refractory B-cell malignancies. CAR-T therapy has been extensively applied in the clinical setting; however, few systematic studies have evaluated the cost of CAR-T treatment. This study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Feng, Wei, Guoqing, Zhang, Mingming, Zhao, Houli, Wu, Wenjun, Yang, Luxin, Hu, Yongxian, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444226/
https://www.ncbi.nlm.nih.gov/pubmed/32314613
http://dx.doi.org/10.1177/0963689720919434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444226/
https://www.ncbi.nlm.nih.gov/pubmed/32314613
http://dx.doi.org/10.1177/0963689720919434

Ejemplares similares